The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
AstraZeneca is extending the reach of its legal team as it hunts for litigators to inspect the patents of acquisition targets in order to find weaknesses in their IP portfolios. The company is currently restructuring its legal group and appointing a new general counsel for subsidiary Cambridge Antibody Technology (CAT).
AstraZeneca wants to buy up smaller patent-owning companies to boost its drug pipeline. The plan is key to AstraZeneca's business strategy.
Andrew Farquharson, director of biotech patents at AstraZeneca, said: "We're looking at some external law firms to advise on this. It's normal practice to look at the patents."
Meanwhile, CAT, one of AstraZeneca's biggest acquisitions of 2006, has restructured its legal team. General counsel Diane Mellett has left, to be replaced by former AstraZeneca senior counsel Adrian Kemp.